Latest Medical Devices News

Cochlear Limited posted a 5% increase in sales revenue to $1.17 billion for the half year ended December 2024, driven by strong cochlear and acoustic implant growth despite a decline in Services revenue. The company anticipates FY25 underlying net profit at the lower end of guidance amid increased cloud investments and prepares for new product launches.

Cochlear Limited has announced a fully franked dividend of AUD 2.15 per share for the six months ending December 2024, payable in multiple currencies on April 14, 2025.

Cochlear Limited has reported a robust half-year performance with a 7% increase in underlying net profit and an 8% rise in interim dividends, driven by strong sales in cochlear and acoustic implants despite a decline in services revenue.

Visioneering Technologies Inc. has requested an immediate suspension from ASX trading as it prepares for removal from the official list, raising questions about the company’s future.

Osteopore Limited has announced a $20 million convertible notes offering aimed at bolstering its capital for ongoing operations and future projects. The highly speculative offer targets sophisticated investors and underscores the company’s strategic funding approach amid competitive medical device markets.

EMVision Medical Devices has secured US ethics approval for its pivotal multi-centre trial of the EMVision emu™ brain scanner, paving the way for a March 2025 trial start aimed at FDA clearance.

SomnoMed Limited prepares to unveil its H1FY25 financial results on February 28, 2025, accompanied by a live investor presentation and Q&A session. The company remains a global leader in sleep apnea treatment solutions.

Gyder Surgical, backed by Hydrix Ventures, has secured FDA 510(k) clearance for its innovative GYDER Hip System, opening the door to the lucrative U.S. market and increasing Hydrix’s investment value.

Ansell Limited has announced a USD 0.222 per share dividend for the six months ending December 2024, payable in March 2025 with a full dividend reinvestment plan available.

Micro-X Limited has requested an immediate voluntary suspension of its shares on the ASX, pending a forthcoming equity raising announcement expected by February 10.

OncoSil Medical has secured authorization for 120 German hospitals to negotiate funding for its pancreatic cancer treatment device, marking a 43% increase from last year and signaling growing acceptance in Germany’s healthcare system.

dorsaVi has secured a new commercial research project with renowned US surgeon Dr. Chirag Patel, leveraging its FDA-cleared wearable sensor technology and AI to enhance injury prevention and performance for elite athletes.